Na Zhao

9PUBLICATIONS
33CO-AUTHORS
Innate immunityMolecular targetsMicroelectromechanical systems (MEMS)Cancer therapy (excl. chemotherapy and radiation therapy)Microbial genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 10, 2026
Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity.

|Aug 17, 2026
MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer.

|Feb 27, 2026
CELF1 is a non-canonical eIF4E binding protein that promotes translation of epithelial-mesenchymal transition effector mRNAs.

Arindam Chaudhury, Natee Kongchan, Shebna A Massey

|Jan 03, 2026
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

Diego A Pedroza, Xueying Yuan, Fengshuo Liu

|Jun 26, 2025
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers.

Diego A Pedroza, Xueying Yuan, Fengshuo Liu

|Dec 23, 2024
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.

Jonathan T Lei, Lacey E Dobrolecki, Chen Huang

Pageof 2

Frequent Collaborators

6 joint publications

Jeffrey M Rosen

4 joint publications

Diego A Pedroza

4 joint publications

Xiang H-F Zhang

3 joint publications

Fengshuo Liu